Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

The user is using a combination of oral Dutasteride and Minoxidil, and a topical formula with Finasteride, Minoxidil, and Hydrocortisone, along with rosemary oil, coconut oil, ginseng, and a derma roller. They are also using LLLT therapy and are questioning the timing of the laser cap session in relation to the topical application.

The user shared a 6-month aggressive hair loss treatment progress, using oral minoxidil, finasteride/minoxidil topical, dutasteride, derma stamping, Nizoral, and daily Cialis, which notably improved regrowth. Commenters observed significant improvement, with one noting a change from a Norwood 5 to a Norwood 1 in hair loss classification.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

People are frustrated with hair loss treatments like finasteride, minoxidil, and dutasteride, with mixed results and side effects. Some users suggest trying different combinations or doses, while others express disappointment and hope for a cure.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Hair loss discussion includes Latanoprost as potential treatment. Mild improvement observed with its use.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

People are sharing their experiences of keeping a hidden folder on their phones with photos documenting their hair loss. Some users discuss the emotional impact, while one mentions using dutasteride and oral minoxidil without noticeable change.

Hair loss discussion includes topical latanoprost and melatonin. Users share regimens and products used for treatment.

The user has been on 1mg finasteride for a year, experiencing low libido and moderate erectile issues. They are considering using Cialis daily with finasteride long term to address these side effects.

Caffeine may promote hair growth and potentially inhibit 5-α-reductase activity in hair follicles, but its effectiveness and systemic impact remain unclear. Users discuss using topical caffeine solutions, with some experiencing no side effects compared to finasteride.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

Latanoprost for hair loss is available in Canada at Ford's Family Pharmacy in New Brunswick, with up to 0.03% concentration, six times stronger than glaucoma medication Xalatan.

The conversation discusses avoiding caffeine after Platelet-Rich Plasma (PRP) treatment for hair loss because caffeine is a vasoconstrictor, which can reduce blood flow and hinder the healing process that PRP aims to promote.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

The user experiences scalp inflammation, especially when oily, despite using treatments like dutasteride, oral minoxidil, RU58841, and nizoral. They recently started cetirizine and are considering benzoyl peroxide wash for relief.

The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.

The user has been experiencing hair loss since having COVID and has low vitamin D levels; they are seeing some improvement in their crown and hairline after starting vitamin D supplements. Commenters suggest the hair loss pattern is consistent with male pattern baldness (MPD) and varies by individual.

The conversation is about sourcing Latanoprost for hair loss treatment. Users discuss potential sources and the difficulty of obtaining a prescription.

The user has been using oral minoxidil, finasteride, and dutasteride to prevent hair loss, despite not showing significant balding. Many commenters believe the treatment is excessive, while some support early prevention.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

A user experienced rapid hair loss and was prescribed Desonide cream for mild Alopecia. They are seeking feedback on its effectiveness and potential side effects.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.

A user is combining topical finasteride with minoxidil and considering adding oral finasteride to their routine. Others share their experiences with similar treatments, including oral dutasteride and minoxidil, and discuss cost and dosage concerns.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.